Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Where Arrowhead Pharmaceuticals Stands With Analysts
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…
By David Bautz, PhD
NASDAQ:ARWR
READ THE FULL ARWR RESEARCH REPORT
Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $80
Chardan Capital maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $94 to $80.
Baird Upgrades Arrowhead Pharmaceuticals to Outperform, Lowers Price Target to $60
Baird analyst Joel Beatty upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) from Neutral to Outperform and lowers the price target from $71 to $60.
SVB Leerink Maintains Market Perform on Arrowhead Pharmaceuticals, Lowers Price Target to $35
SVB Leerink analyst Mani Foroohar maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Market Perform and lowers the price target from $36 to $35.
Arrowhead Pharmaceuticals: Q2 Earnings Insights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.